An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents

Approximately 2.1 million of the estimated 36 million infected with HIV are children or adolescents. International guidelines for HIV-1 Infection suggest starting antiretrovirals (ARV) at the moment of diagnosis. Many factors limit the optimization of antiretroviral therapy in children and adolescen...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on pharmacotherapy Vol. 20; no. 3; p. 269
Main Authors Giacomet, Vania, Cossu, Maria V, Capetti, Amedeo F, Zuccotti, GianVincenzo, Rizzardini, Giuliano
Format Journal Article
LanguageEnglish
Published England 11.02.2019
Subjects
Adenine - administration & dosage
Adenine - analogs & derivatives
Adolescent
Anti-HIV Agents - administration & dosage
Child
Cobicistat - administration & dosage
Emtricitabine - administration & dosage
HIV Infections - drug therapy
Humans
Quinolones - administration & dosage
Tablets
United States
United States Food and Drug Administration
United States
Elvitegravir
adolescent
cobicistat
children
antiretroviral therapy
Online AccessGet more information

Cover

More Information
Summary:Approximately 2.1 million of the estimated 36 million infected with HIV are children or adolescents. International guidelines for HIV-1 Infection suggest starting antiretrovirals (ARV) at the moment of diagnosis. Many factors limit the optimization of antiretroviral therapy in children and adolescents: lack of pediatric formulations, poor adherence, metabolic and pharmacokinetic changes associated withnormal child development and puberty. Areas covered: Three integrase inhibitors are approved by the US Food and Drug Administration and by European Medical Agency for children and adolescents with HIV-1 infection. Raltegravir is approved for children aged 4 weeks to 18 years, while dolutegravir and elvitegravir co-formulated with cobicistat, emtricitabine, and tenofovir alafenamide (E/C/FTC/TAF) are approved for children from 6 years of age. This article evaluates E/C/FTC/TAF as a treatment option. Expert opinion: E/C/FTC/TAF was well tolerated, and the antiretroviral activity and tolerability data of this combination support the use in children and adolescents. However, the studies regarding E/C/FTC/TAF in children and adolescents are scant. Consequently, additional studies investigating its safety and efficacy in children are paramount.
ISSN:1744-7666
DOI:10.1080/14656566.2018.1559299